Evidence & audit

Where every number comes from, and what could not be verified

This work was audited against itself: 292 checkable claims traced to source, 73 derived figures independently recomputed, and five adversarial reviewers across four AI labs instructed to destroy it. The defects they found are listed here rather than buried.

0.00%Confirmed fabrications across 292 claims
6Model bugs found and fixed
10Overclaims corrected
60%Of model inputs that are judgement, not evidence

Primary sources

The corrections that mattered

Six model bugs

1. Payroll charged an extra month's salary instead of the flat MVR 3,000 Ramadan allowance the research had verified. 2. Card merchant fees were charged on wholesale revenue, which is invoiced on 35-day credit. 3. Store 1's fit-out capex and rent deposit were never charged at all — MVR 674,505 of spend that simply never happened, because the trigger condition could never be true for a store opening in month 1. 4. Working-capital overrides were silently inert, so every stock-cover and supplier-credit sensitivity was meaningless. 5 and 6. Two arithmetic slips in published tables — a MVR 1,000 sum and an FX conversion using 15.4173 instead of 15.42.

The first three all pushed the same way: they overstated costs, so the published figures understated performance. The balance sheet still tied throughout — an absent transaction never unbalances anything, which is exactly why a tie is not proof of correctness.

Ten overclaims

The most consequential was in the opening sentence of the deck: “Not one formal retail chain in the country stocks a Korean brand.” The six chains verified — grocery, pharmacy, duty-free — genuinely carry none, but Le Cute, the country's leading prestige beauty retailer, already stocks Medicube and Round Lab. The claim was too broad and is now narrowed.

Others: describing agreement with the Maldives Monetary Authority's series as independent corroboration, when MMA sources its trade data from Customs; presenting a modelled FX path as a forecast; and a balance-sheet reconciliation of MVR 0.000000 quoted as though it validated the assumptions rather than the code.

What could not be verified

Dated risks

23 October 2026. Medicine Regulation 2026/R-64 makes it an offence for general traders to import or stock “products containing a medicinal substance” without authority permission — MVR 10,000 to 100,000, with port seizure and destruction. The governing phrase is undefined in the regulation. The regulator's own decision tree defers to country-of-origin classification, so Korean functional cosmetics remain cosmetics here unless marketed differently — which makes claim discipline a compliance control, not a marketing preference.